MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Ascendis Pharma A/S NASDAQ:ASND | $18.06B | $275.39 | Not rated | 24.5 | +27.42% |
Rhythm Pharmaceuticals, Inc. NASDAQ:RYTM | $7.97B | $115.02 | Not rated | -33.3 | +15.40% |
Viking Therapeutics, Inc. NASDAQ:VKTX | $3.73B | $29.22 | Not rated | -7.5 | -27.39% |
Xeris Biopharma Holdings, Inc. NASDAQ:XERS | $3.04B | $16.66 | Undervalued | 98.7 | +139.63% |
Kailera Therapeutics, Inc. NASDAQ:KLRA | $1.72B | $13.27 | Not rated | — | — |
Altimmune, Inc. NASDAQ:ALT | $319.98M | $1.65 | Not rated | -3.7 | -69.72% |
Oramed Pharmaceuticals Inc. NASDAQ:ORMP | $154.33M | $3.71 | Not rated | 1.4 | +66.95% |
Biomea Fusion, Inc. NASDAQ:BMEA | $42.31M | $0.58 | Not rated | -1.9 | -33.13% |
Continue the stock analysis
Jump to another research area for this company.